PMID- 26648870 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20151209 LR - 20220409 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 6 DP - 2015 TI - Advances and Challenges of Liposome Assisted Drug Delivery. PG - 286 LID - 10.3389/fphar.2015.00286 [doi] LID - 286 AB - The application of liposomes to assist drug delivery has already had a major impact on many biomedical areas. They have been shown to be beneficial for stabilizing therapeutic compounds, overcoming obstacles to cellular and tissue uptake, and improving biodistribution of compounds to target sites in vivo. This enables effective delivery of encapsulated compounds to target sites while minimizing systemic toxicity. Liposomes present as an attractive delivery system due to their flexible physicochemical and biophysical properties, which allow easy manipulation to address different delivery considerations. Despite considerable research in the last 50 years and the plethora of positive results in preclinical studies, the clinical translation of liposome assisted drug delivery platforms has progressed incrementally. In this review, we will discuss the advances in liposome assisted drug delivery, biological challenges that still remain, and current clinical and experimental use of liposomes for biomedical applications. The translational obstacles of liposomal technology will also be presented. FAU - Sercombe, Lisa AU - Sercombe L AD - The School of Biomedical Sciences and Pharmacy, The University of Newcastle Callaghan, NSW, Australia ; Hunter Medical Research Institute, New Lambton Heights NSW, Australia. FAU - Veerati, Tejaswi AU - Veerati T AD - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA ; Department of Biochemistry and Cell Biology, Rice University Houston, TX, USA. FAU - Moheimani, Fatemeh AU - Moheimani F AD - The School of Biomedical Sciences and Pharmacy, The University of Newcastle Callaghan, NSW, Australia ; Hunter Medical Research Institute, New Lambton Heights NSW, Australia. FAU - Wu, Sherry Y AU - Wu SY AD - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA. FAU - Sood, Anil K AU - Sood AK AD - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA ; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center Houston, TX, USA ; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center Houston, TX, USA. FAU - Hua, Susan AU - Hua S AD - The School of Biomedical Sciences and Pharmacy, The University of Newcastle Callaghan, NSW, Australia ; Hunter Medical Research Institute, New Lambton Heights NSW, Australia. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States GR - UH2 TR000943/TR/NCATS NIH HHS/United States GR - R01 CA177909/CA/NCI NIH HHS/United States GR - R01 CA109298/CA/NCI NIH HHS/United States GR - P50 CA098258/CA/NCI NIH HHS/United States GR - P50 CA083639/CA/NCI NIH HHS/United States PT - Journal Article PT - Review DEP - 20151201 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC4664963 OTO - NOTNLM OT - accelerated blood clearance OT - biological challenges OT - complement activation-related pseudoallergy OT - drug delivery OT - lipid-based drug delivery system OT - liposomes OT - nanotechnology OT - translation EDAT- 2015/12/10 06:00 MHDA- 2015/12/10 06:01 PMCR- 2015/12/01 CRDT- 2015/12/10 06:00 PHST- 2015/07/31 00:00 [received] PHST- 2015/11/16 00:00 [accepted] PHST- 2015/12/10 06:00 [entrez] PHST- 2015/12/10 06:00 [pubmed] PHST- 2015/12/10 06:01 [medline] PHST- 2015/12/01 00:00 [pmc-release] AID - 10.3389/fphar.2015.00286 [doi] PST - epublish SO - Front Pharmacol. 2015 Dec 1;6:286. doi: 10.3389/fphar.2015.00286. eCollection 2015.